Division of Cancer Medicine, Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030-4009, USA.
Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba.
The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has altered the landscape of therapeutic options for multiple myeloma by offering new mechanisms for targeting this disease. Combinations of these agents, with each other and/or traditional chemotherapeutics, have vastly increased the treatment options for patients both frontline, and at relapse, providing higher response rates, and importantly, increasing median overall survival. In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma.
新型药物的引入，如沙利度胺、硼替佐米和来那度胺，通过提供针对这种疾病的新机制，改变了多发性骨髓瘤的治疗选择格局。这些药物与其他药物（包括传统化疗药物）的组合，极大地增加了患者的治疗选择，无论是一线治疗还是复发后治疗，提供了更高的缓解率，并且重要的是，增加了中位总生存期。在这篇综述中，我们将讨论这些新型药物及其组合在复发和/或难治性多发性骨髓瘤患者中的应用。
